Antibacterial agent for treating urinary system infection as well as preparation method and application of antibacterial agent

Abstract

The invention belongs to the technical field of antibacterial products, and particularly relates to an antibacterial agent for treating urinary system infection and a preparation method and application thereof. The antibacterial agent for treating urinary system infection is composed of chlorhexidine and a calcium liquid, the mass ratio of chlorhexidine to the calcium liquid is 0.4-0.7: 100, and the concentration of the calcium liquid is 0.05 g / 100 mL to 0.5 g / 100 mL. The prepared antibacterial agent for urinary system infection can be used for treating staphylococcus aureus, escherichia coli, candida albicans, pseudomonas aeruginosa and bacillus subtilis, and particularly can be used for treating methicillin-resistant staphylococcus aureus, so that infection caused by the staphylococcus aureus, the escherichia coli, the candida albicans, the pseudomonas aeruginosa and the bacillus subtilis is treated.

Description

Technical Field

[0001] The present invention belongs to the technical field of antibacterial products, and in particular relates to an antibacterial agent for treating urinary tract infection, and a preparation method and application thereof. Background Art

[0002] Urinary tract infection refers to an infectious disease caused by the abnormal reproduction of pathogens in the urinary tract. The most common pathogens of urinary tract infection are bacteria, among which Escherichia coli is the most important pathogen. Proteus, Klebsiella, Staphylococcus, etc. are also common bacteria that cause urinary tract infection. In addition to bacteria, fungi, viruses, chlamydia, mycoplasma, etc. may also cause urinary tract infection. Fungal urinary tract infection usually occurs in patients who use antibiotics for a long time, have low immune function or have an indwelling catheter. Urinary tract infection brings many inconveniences to patients' daily lives and seriously affects their quality of life. Therefore, the treatment of urinary tract infection is of great significance.

[0003] At present, the main treatment for urinary tract infections is antibiotics. Antimicrobial drugs include β-lactams, such as penicillins and cephalosporins, which inhibit bacterial cell wall synthesis and exert their antibacterial effects; they also include quinolones, which inhibit bacterial DNA gyrase and topoisomerase IV, hinder DNA replication and inhibit bacteria, and have good antibacterial activity against Gram-negative bacteria and some Gram-positive bacteria; they also include sulfonamides, whose mechanism of action is to inhibit bacterial growth and reproduction by interfering with bacterial folate metabolism. The above-mentioned antimicrobial agents have the advantages of rapid effect and broad antibacterial spectrum, but if antimicrobial agents are used excessively, some patients will develop drug resistance, so it is necessary to continue to develop new antimicrobial agents. Summary of the invention

[0004] In order to solve the above technical problems, the present invention provides an antibacterial agent for treating urinary tract infection and a preparation method and application thereof.

[0005] The invention aims to provide an antibacterial agent for treating urinary system infection, which is composed of chlorhexidine and calcium liquid, wherein the mass ratio of chlorhexidine to calcium liquid is 0.4-0.7:100, and the concentration of calcium liquid is 0.05g / 100mL-0.5g / 100mL.

[0006] The calcium in the calcium liquid is used to regulate cell metabolic activities, enhance the antibacterial ability of chlorhexidine, and reduce the drug resistance of drug-resistant bacteria to chlorhexidine. The antibacterial agent for treating urinary tract infection of the present invention is suitable for inhibiting at least one of Staphylococcus aureus, Escherichia coli, Candida albicans, Pseudomonas aeruginosa and Bacillus subtilis. The antibacterial agent of the present invention is also used to inhibit methicillin-resistant Staphylococcus aureus resistant to chlorhexidine, wherein the methicillin-resistant Staphylococcus aureus is a MRSA strain.

[0007] Preferably, the above-mentioned antibacterial agent for treating urinary tract infection, the calcium liquid is calcium gluconate liquid or calcium citrate liquid. In addition to containing calcium, these two liquids are also organic calcium, and their solubility and absorbability are better than inorganic calcium such as calcium carbonate.

[0008] Preferably, the concentration of the calcium gluconate liquid in the above-mentioned antibacterial agent for treating urinary tract infection is 0.06 g / 100 mL to 0.5 g / 100 mL.

[0009] Preferably, the concentration of the calcium citrate liquid in the above-mentioned antibacterial agent for treating urinary tract infection is 0.05 g / 100 mL to 0.06 g / 100 mL.

[0010] Preferably, in the above-mentioned antibacterial agent for treating urinary tract infection, the solvent of the calcium liquid is sterile water.

[0011] The present invention provides a method for preparing the antibacterial agent for treating urinary tract infection, comprising: preparing chlorhexidine and calcium liquid according to the mass ratio, mixing, and obtaining the antibacterial agent for treating urinary tract infection.

[0012] The present invention provides the application of the above-mentioned antibacterial agent for treating urinary tract infection, and the application refers to mixing the antibacterial agent for treating urinary tract infection with pharmaceutically acceptable auxiliary materials to prepare an antibacterial liquid.

[0013] Preferably, in the use of the above-mentioned antibacterial agent for treating urinary tract infection, the antibacterial liquid is an external wash.

[0014] Preferably, the auxiliary materials corresponding to the external lotion include at least one of (a) to (d): (a) Buffers, such as citric acid-sodium citrate buffer system with a pH of 4.5 to 8.0, can help reduce irritation to the urethra and bladder mucosa. A suitable pH environment is also conducive to the activity of chlorhexidine and calcium liquid.

[0015] (b) Surfactants, such as sodium laureth sulfate, have good cleaning and emulsifying properties.

[0016] (c) Humectants, such as glycerin, absorb moisture from the surrounding environment and keep the mucous membrane moist.

[0017] (d) Preservatives, such as potassium sorbate, are used to prevent contamination of topical washes during storage and use.

[0018] Compared with the prior art, the present invention has the following beneficial effects: The antibacterial agent for treating urinary tract infection provided by the present invention is composed of chlorhexidine and calcium liquid, the mass ratio of chlorhexidine to calcium liquid is 0.4 ~ 0.7:100, and the concentration of calcium liquid is 0.05g / 100mL ~ 0.5g / 100mL. The present invention achieves the purpose of treating urinary tract infection by inhibiting at least one of Staphylococcus aureus, Escherichia coli, Candida albicans, Pseudomonas aeruginosa and Bacillus subtilis, especially has a good antibacterial effect on methicillin-resistant Staphylococcus aureus, and has a wide range of application prospects. In addition, the antibacterial effect of the antibacterial agent for treating urinary tract infection of the present invention can reduce the survival time of these pathogens in the environment, reduce the risk of transmission of pathogens, and protect susceptible populations.

[0019] The present invention also provides an application of an antibacterial agent for urinary tract infection in the preparation of an external wash, which has at least the following advantages: (1) it can remove dirt and eliminate odors, and can keep the cleansed area clean; (2) it can prevent and treat urinary tract infection and relieve inflammatory reactions; (3) it can relieve discomfort such as itching, redness and swelling; and (4) it is simple to use, is a local medication, and has few side effects. BRIEF DESCRIPTION OF THE DRAWINGS

[0020] Figure 1 This is the plate diagram of the antibacterial experiment of methicillin-resistant Staphylococcus aureus in the control group.

[0021] Figure 2 This is the plate diagram of the antibacterial experiment of methicillin-resistant Staphylococcus aureus in experimental group 1.

[0022] Figure 3 This is the plate diagram of the antibacterial experiment of methicillin-resistant Staphylococcus aureus in experimental group 2.

[0023] Figure 4 This is the plate diagram of the antibacterial experiment of methicillin-resistant Staphylococcus aureus in experimental group 3.

[0024] Figure 5 This is the plate diagram of the antibacterial experiment of methicillin-resistant Staphylococcus aureus in experimental group 4.

[0025] Figure 6 This is the plate diagram of the antibacterial experiment of methicillin-resistant Staphylococcus aureus in experimental group 5.

[0026] Figure 7 This is the plate diagram of the antibacterial experiment of methicillin-resistant Staphylococcus aureus in experimental group 6.

[0027] Figure 8 This is the plate diagram of the antibacterial experiment of methicillin-resistant Staphylococcus aureus in experimental group 7.

[0028] Fig. 9This is the plate diagram of the antibacterial experiment of methicillin-resistant Staphylococcus aureus in experimental group 8.

[0029] Fig.10 This is the plate diagram of the antibacterial experiment of methicillin-resistant Staphylococcus aureus in experimental group 9.

[0030] Fig.11 This is the plate diagram of the antibacterial experiment of methicillin-resistant Staphylococcus aureus in experimental group 10.

[0031] Fig.12 This is the plate diagram of the antibacterial experiment of methicillin-resistant Staphylococcus aureus in experimental group 11.

[0032] Fig.13 This is the plate diagram of the antibacterial experiment of methicillin-resistant Staphylococcus aureus in experimental group 12.

[0033] Fig.14 This is the plate diagram of the antibacterial experiment of methicillin-resistant Staphylococcus aureus in experimental group 13.

[0034] Fig.15 This is the plate diagram of the antibacterial experiment of methicillin-resistant Staphylococcus aureus in experimental group 14. DETAILED DESCRIPTION

[0035] In order to enable those skilled in the art to better understand and implement the technical solution of the present invention, the present invention is further described below in conjunction with specific embodiments and drawings.

[0036] In the description of the present invention, unless otherwise specified, all reagents used are commercially available and all methods used are conventional techniques in the art.

[0037] Example 1 An antibacterial agent for treating urinary tract infection is composed of 0.4 g of chlorhexidine and 100 mL of calcium liquid. The calcium liquid is calcium citrate liquid, the concentration of the calcium citrate liquid is 0.05 g / 100 mL, and the solvent of the calcium citrate liquid is sterile water.

[0038] The preparation method of the antibacterial agent for treating urinary tract infection is as follows: prepare 0.4 g of chlorhexidine and 100 mL of calcium liquid, mix them, and obtain the antibacterial agent for treating urinary tract infection.

[0039] Example 2 An antibacterial agent for treating urinary tract infection is composed of 0.5 g of chlorhexidine and 100 mL of calcium liquid. The calcium liquid is calcium citrate liquid, the concentration of the calcium citrate liquid is 0.05 g / 100 mL, and the solvent of the calcium citrate liquid is sterile water.

[0040] The preparation method of the antibacterial agent for treating urinary tract infection is as follows: prepare 0.5 g of chlorhexidine and 100 mL of calcium liquid, mix them, and obtain the antibacterial agent for treating urinary tract infection.

[0041] Example 3 An antibacterial agent for treating urinary tract infection is composed of 0.6 g of chlorhexidine and 100 mL of calcium liquid. The calcium liquid is calcium citrate liquid, the concentration of the calcium citrate liquid is 0.05 g / 100 mL, and the solvent of the calcium citrate liquid is sterile water.

[0042] The preparation method of the antibacterial agent for treating urinary tract infection is as follows: prepare 0.6 g of chlorhexidine and 100 mL of calcium liquid, mix them, and obtain the antibacterial agent for treating urinary tract infection.

[0043] Example 4 An antibacterial agent for treating urinary tract infection is composed of 0.7 g of chlorhexidine and 100 mL of calcium liquid. The calcium liquid is calcium citrate liquid, the concentration of the calcium citrate liquid is 0.05 g / 100 mL, and the solvent of the calcium citrate liquid is sterile water.

[0044] The preparation method of the antibacterial agent for treating urinary tract infection is as follows: prepare 0.7 g of chlorhexidine and 100 mL of calcium liquid, mix them, and obtain the antibacterial agent for treating urinary tract infection.

[0045] Example 5 An antibacterial agent for treating urinary tract infection is composed of 0.4 g of chlorhexidine and 100 mL of calcium liquid. The calcium liquid is calcium citrate liquid, the concentration of the calcium citrate liquid is 0.06 g / 100 mL, and the solvent of the calcium citrate liquid is sterile water.

[0046] The preparation method of the antibacterial agent for treating urinary tract infection is as follows: prepare 0.4 g of chlorhexidine and 100 mL of calcium liquid, mix them, and obtain the antibacterial agent for treating urinary tract infection.

[0047] Example 6 An antibacterial agent for treating urinary system infection is composed of 0.4 g of chlorhexidine and 100 mL of calcium liquid. The calcium liquid is calcium gluconate liquid, the concentration of the calcium gluconate liquid is 0.05 g / 100 mL, and the solvent of the calcium gluconate liquid is sterile water.

[0048] The preparation method of the antibacterial agent for treating urinary tract infection is as follows: prepare 0.4 g of chlorhexidine and 100 mL of calcium liquid, mix them, and obtain the antibacterial agent for treating urinary tract infection.

[0049] Example 7 An antibacterial agent for treating urinary system infection is composed of 0.5 g of chlorhexidine and 100 mL of calcium liquid. The calcium liquid is calcium gluconate liquid, the concentration of the calcium gluconate liquid is 0.05 g / 100 mL, and the solvent of the calcium gluconate liquid is sterile water.

[0050] The preparation method of the antibacterial agent for treating urinary tract infection is as follows: prepare 0.5 g of chlorhexidine and 100 mL of calcium liquid, mix them, and obtain the antibacterial agent for treating urinary tract infection.

[0051] Example 8 An antibacterial agent for treating urinary system infection is composed of 0.6 g of chlorhexidine and 100 mL of calcium liquid. The calcium liquid is calcium gluconate liquid, the concentration of the calcium gluconate liquid is 0.05 g / 100 mL, and the solvent of the calcium gluconate liquid is sterile water.

[0052] The preparation method of the antibacterial agent for treating urinary tract infection is as follows: prepare 0.6 g of chlorhexidine and 100 mL of calcium liquid, mix them, and obtain the antibacterial agent for treating urinary tract infection.

[0053] Example 9 An antibacterial agent for treating urinary tract infection is composed of 0.7 g of chlorhexidine and 100 mL of calcium liquid. The calcium liquid is calcium gluconate liquid, the concentration of the calcium gluconate liquid is 0.05 g / 100 mL, and the solvent of the calcium gluconate liquid is sterile water.

[0054] The preparation method of the antibacterial agent for treating urinary tract infection is as follows: prepare 0.7 g of chlorhexidine and 100 mL of calcium liquid, mix them, and obtain the antibacterial agent for treating urinary tract infection.

[0055] Example 10 An antibacterial agent for treating urinary system infection is composed of 0.4 g of chlorhexidine and 100 mL of calcium liquid. The calcium liquid is calcium gluconate liquid, the concentration of the calcium gluconate liquid is 0.1 g / 100 mL, and the solvent of the calcium gluconate liquid is sterile water.

[0056] The preparation method of the antibacterial agent for treating urinary tract infection is as follows: prepare 0.4 g of chlorhexidine and 100 mL of calcium liquid, mix them, and obtain the antibacterial agent for treating urinary tract infection.

[0057] Embodiment 11 An antibacterial agent for treating urinary system infection is composed of 0.4 g of chlorhexidine and 100 mL of calcium liquid. The calcium liquid is calcium gluconate liquid, the concentration of the calcium gluconate liquid is 0.5 g / 100 mL, and the solvent of the calcium gluconate liquid is sterile water.

[0058] The preparation method of the antibacterial agent for treating urinary tract infection is as follows: prepare 0.4 g of chlorhexidine and 100 mL of calcium liquid, mix them, and obtain the antibacterial agent for treating urinary tract infection.

[0059] The main differences between the above embodiments are shown in Table 1. In Table 1, the conditions of other experimental groups are also set, wherein the control group is sterile water, the chlorhexidine group is the liquid after chlorhexidine is dispersed in sterile water, the calcium gluconate liquid group is the liquid after calcium gluconate is dispersed in sterile water, and the calcium citrate liquid group is the liquid after calcium citrate is dispersed in sterile water. The difference between Examples 1 to 4 is the mass ratio of chlorhexidine and calcium citrate liquid, in order to explore the influence of different mass ratios of chlorhexidine and calcium citrate liquid on the antibacterial effect. The concentrations of different calcium citrate liquids are used in Examples 1 and 5, in order to explore the influence of different concentrations of calcium citrate liquid on the antibacterial effect. The difference between Examples 6 to 9 is the mass ratio of chlorhexidine and calcium gluconate liquid, in order to explore the influence of different mass ratios of chlorhexidine and calcium gluconate liquid on the antibacterial effect. The concentrations of different calcium gluconate liquids are used in Examples 5, 10 and 11, in order to explore the influence of different concentrations of calcium gluconate liquid on the antibacterial effect.

[0060] Table 1 Formulas of different experimental groups

[0061] 1. Antibacterial experiment of methicillin-resistant Staphylococcus aureus.

[0062] (1) Name of the strain: Methicillin-resistant Staphylococcus aureus.

[0063] (2) Preparation of bacterial suspension Material preparation: Activate methicillin-resistant Staphylococcus aureus. At the same time, prepare a 0.9% sodium chloride solution and sterilize it to obtain sterile physiological saline.

[0064] Operation steps: Pick the activated strain and place it in a sterile test tube filled with sterile saline. Use a vortex oscillator to evenly disperse the bacteria to form a bacterial suspension. Use sterile saline to adjust the concentration of the bacterial suspension until the concentration of the bacterial suspension is adjusted to 2.0×10 4 cfu / mL.

[0065] (3) Antibacterial rate detection Detection process: In the clean bench, take the prepared concentration of 2.0×10 4100 μL of bacterial suspension with cfu / mL was added to 5 mL of the liquid to be tested and mixed to obtain a mixed sample. After 20 minutes, 0.5 mL of the mixed sample was added to the nutrient agar medium at 42°C, mixed and poured into a culture dish. After the nutrient agar medium solidified, it was cultured at 37°C for 48 hours. After the culture was completed, the number of live bacterial colonies was counted. Repeat the test three times and take the average number of live bacterial colonies.

[0066] The antibacterial rate was calculated according to the following formula: .

[0067] The test results are shown in Table 2. The plate diagram of the antibacterial test of methicillin-resistant Staphylococcus aureus is shown in Figure 1 to Figure 15 .

[0068] Table 2 Inhibition rate of methicillin-resistant Staphylococcus aureus

[0069] Methicillin-resistant Staphylococcus aureus is a multidrug-resistant bacterium, and the harm it brings is mainly reflected in the following aspects.

[0070] (1) Difficulty in clinical treatment: MRSA is resistant to a variety of commonly used antibiotics, including methicillin. Commonly used penicillins and cephalosporins are usually ineffective against it. It is necessary to use expensive antibiotics such as vancomycin and linezolid that have more toxic side effects. Therefore, it is necessary to develop new antimicrobial agents for MRSA.

[0071] (2) High morbidity and mortality: MRSA can infect people of all ages and health conditions. Special populations such as hospitalized patients, the elderly, and children have poor resistance. Once infected with MRSA, the disease often progresses rapidly, leading to higher morbidity and mortality. In addition, MRSA can cause serious infections such as skin and soft tissue infections, bloodstream infections, pneumonia, osteomyelitis, and endocarditis. Taking bloodstream infection as an example, after the bacteria enter the blood, they will spread to various organs throughout the body through the blood circulation, triggering a systemic inflammatory response syndrome, which can lead to septic shock and multiple organ failure in severe cases.

[0072] In view of the fact that methicillin-resistant Staphylococcus aureus currently exhibits resistance to chlorhexidine, it is necessary to develop products that can improve chlorhexidine resistance. The antibacterial agent for treating urinary tract infection provided by the present invention has an inhibitory effect on methicillin-resistant Staphylococcus aureus, reduces the infection symptoms of methicillin-resistant Staphylococcus aureus, can improve respiratory function, and improve the quality of life of patients.

[0073] 2. Antibacterial experiments on other strains.

[0074] (1) Name of strain Staphylococcus aureus ATCC6538, Escherichia coli ATCC25922, Candida albicans ATCC10231, Pseudomonas aeruginosa ATCC9027 and Bacillus subtilis ATCC21394.

[0075] (2) Preparation of bacterial suspension Material preparation: Staphylococcus aureus ATCC6538, Escherichia coli ATCC25922, Candida albicans ATCC1023, Pseudomonas aeruginosa ATCC9027 and Bacillus subtilis ATCC21394 were activated respectively. At the same time, a sodium chloride solution with a mass fraction of 0.9% was prepared and sterilized to obtain sterile physiological saline.

[0076] Operation steps: Pick each activated strain and place them in a sterile test tube filled with sterile saline. Use a vortex oscillator to evenly disperse the bacteria to form a bacterial suspension. Use sterile saline to adjust the concentration of the bacterial suspension until the concentration of each strain is adjusted to 2.0×10 4 cfu / mL.

[0077] (3) Antibacterial rate detection Detection process: In the clean bench, take the prepared concentration of 2.0×10 4 100 μL of bacterial suspension with cfu / mL was added to 5 mL of the liquid to be tested, and mixed to obtain a mixed sample. After 20 minutes, 0.5 mL of the mixed sample was taken for gradient dilution. The liquids before and after dilution were added to the culture medium at 42°C, mixed and poured into the culture dish. After the culture medium solidified, it was cultured at 35°C. Among them, the culture medium used for Staphylococcus aureus ATCC6538, Escherichia coli ATCC25922, Pseudomonas aeruginosa ATCC9027 and Bacillus subtilis ATCC21394 was nutrient agar medium, and the culture time at 35°C was 48h. The culture medium used for Candida albicans ATCC10231 was Sabouraud agar medium, and the culture time at 35°C was 72h. After the culture was completed, the number of viable colonies was counted. Repeat the test three times and take the average number of viable colonies.

[0078] The test results are shown in Table 3. The test liquids corresponding to each experimental group in Table 3 refer to Table 1.

[0079] Table 3 Inhibition rate of other strains

[0080] The results in Table 3 show that the antibacterial agents for treating urinary tract infections of Examples 1 to 11 have good inhibitory effects on Staphylococcus aureus, Escherichia coli, Candida albicans, Pseudomonas aeruginosa, and Bacillus subtilis.

[0081] Staphylococcus aureus, Escherichia coli, Candida albicans, Pseudomonas aeruginosa and Bacillus subtilis are all common pathogens in urinary tract infections. Effectively inhibiting these pathogens has at least the following benefits for urinary tract infections.

[0082] (1) Eliminate the source of infection The massive reproduction of bacteria such as Staphylococcus aureus, Escherichia coli, Pseudomonas aeruginosa, and Bacillus subtilis can damage tissues such as the urinary tract mucosa and cause inflammation. When these bacteria are effectively inhibited, the number of bacteria is greatly reduced and they cannot continue to reproduce in large numbers, thus reducing direct damage to tissues.

[0083] (2) Relieve symptoms When the urinary tract is infected, due to the stimulation of bacteria, patients often experience symptoms such as frequent urination, urgency, and pain when urinating. When these pathogens are eliminated, the inflammation of the urinary tract mucosa gradually subsides, the stimulation to the bladder and urethra is reduced, and abnormal urination is alleviated. For example, in cystitis caused by Pseudomonas aeruginosa infection, patients have frequent urges to urinate and unbearable pain when urinating. After suppressing the bacteria, the inflammation of the bladder mucosa improves, and the symptoms of frequent urination and pain when urinating are relieved. When some patients have urinary tract infections, they will also experience lower abdominal pain, a feeling of heaviness, and systemic symptoms such as fever and chills. For example, toxins produced by bacteria such as Staphylococcus aureus will enter the blood and affect the whole body. After suppressing the bacteria, the production of toxins is reduced, and the body's immune response gradually returns to normal, which helps to relieve lower abdominal discomfort, lower body temperature, alleviate systemic symptoms, and restore the patient's body to a comfortable state.

[0084] (3) Prevent complications If the infection caused by Staphylococcus aureus, Escherichia coli, Pseudomonas aeruginosa, and Bacillus subtilis is not effectively controlled, the bacteria may ascend to infect the kidneys and cause serious diseases such as pyelonephritis. For example, when Escherichia coli and other pathogens infect the kidneys, they will damage kidney tissue and affect kidney function. Timely inhibition of these pathogens can effectively prevent the spread of infection to the kidneys, protect the normal structure and function of the kidneys, and prevent the occurrence of serious complications such as renal dysfunction and renal abscesses. When the bacteria in the blood multiply in large numbers, sepsis may occur, which is a serious and potentially life-threatening disease. Staphylococcus aureus, Pseudomonas aeruginosa, etc. are highly pathogenic. If they are not suppressed in time during urinary tract infections, they may enter the blood, and in severe cases, they may induce sepsis. Therefore, inhibiting these pathogens can significantly reduce the risk of sepsis and protect the lives of patients.

[0085] In summary, the antibacterial agent for treating urinary tract infection provided by the present invention can effectively inhibit Staphylococcus aureus, Escherichia coli, Pseudomonas aeruginosa, and Bacillus subtilis, especially can inhibit methicillin-resistant Staphylococcus aureus, thereby effectively preventing and treating urinary tract infection.

[0086] It should be noted that when the present invention involves a numerical range, it should be understood that the two endpoints of each numerical range and any value between the two endpoints can be selected. Since the steps and methods used are the same as those in the embodiments, in order to avoid redundancy, the present invention describes a preferred embodiment. Although the preferred embodiments of the present invention have been described, once those skilled in the art know the basic inventive concept, they can make other changes and modifications to these embodiments, and these changes and modifications all fall within the scope of the present invention.

[0087] Obviously, those skilled in the art can make various changes and modifications to the present invention without departing from the spirit and scope of the present invention. If these modifications and variations of the present invention fall within the scope of the equivalent technology of the present invention, the present invention is also intended to include these modifications and variations.

Claims

1. An antibacterial agent for treating urinary tract infection, characterized in that: It is composed of chlorhexidine and calcium liquid, the mass ratio of chlorhexidine to calcium liquid is 0.4 ~ 0.7:100, and the concentration of calcium liquid is 0.05g / 100mL ~ 0.5g / 100mL.

2. The antibacterial agent for treating urinary tract infection according to claim 1, characterized in that: The calcium liquid is calcium gluconate liquid or calcium citrate liquid.

3. The antibacterial agent for treating urinary tract infection according to claim 2, characterized in that: The concentration of the calcium gluconate liquid is 0.06 g / 100 mL to 0.5 g / 100 mL.

4. The antibacterial agent for treating urinary tract infection according to claim 2, characterized in that: The concentration of the calcium citrate liquid is 0.05 g / 100 mL to 0.06 g / 100 mL.

5. The antibacterial agent for treating urinary tract infection according to claim 1, characterized in that: The solvent of the calcium liquid is sterile water.

6. The antibacterial agent for treating urinary tract infection according to claim 1, characterized in that: The treatment of urinary system infection refers to the treatment of infection caused by at least one of Staphylococcus aureus, Escherichia coli, Candida albicans, Pseudomonas aeruginosa, and Bacillus subtilis.

7. The antibacterial agent for treating urinary tract infection according to claim 6, characterized in that: The Staphylococcus aureus is methicillin-resistant Staphylococcus aureus.

8. A method for preparing an antibacterial agent for treating urinary tract infection, characterized in that: The chlorhexidine and the calcium liquid are prepared according to the mass ratio of claim 1, and mixed to obtain the antibacterial agent for treating urinary tract infection.

9. Use of an antibacterial agent for treating urinary tract infection in the preparation of an antibacterial liquid, characterized in that: The application refers to mixing the antibacterial agent for treating urinary tract infection described in claim 1 with pharmaceutically acceptable excipients to prepare an antibacterial liquid.

10. Use of the antibacterial agent for treating urinary tract infection according to claim 9 in preparing an antibacterial liquid, characterized in that: The antibacterial liquid is an external washing liquid.

Images